Lowest Price Guaranteed
Pages
187
Last Updated
September 2024
View Count
11119
Chapter 2 presents an executive summary of the report. The summary offers an insight to key highlights of the whole cell based immunotherapies and where the market is headed in the mid-long term.
Chapter 3 provides a general introduction to the market. In this section, we have briefly discussed the conventional therapies being used for oncology treatment, the advent of cancer immunotherapy and, specifically, the emergence DCT and CAR-T.
Chapter 4 provides a comprehensive landscape of the whole cell based immunotherapy market. This chapter includes information on over 40 molecules which are currently in different stages of development (both clinical and pre-clinical / discovery). The detailed analysis of this development pipeline includes information on therapy class, most commonly targeted indications and current phases of development.
Chapter 5 focuses on DCT and presents the current scenario and the future outlook of this specific class of vaccines. The chapter includes detailed profiles of marketed and late stage products. We have presented information on several parameters such as history of development, clinical trial results, manufacturing, cost and reimbursement. It includes the likely sales forecast of the drugs currently in Phase III or higher stage of development.
Chapter 6 focuses on CAR-T and presents the current scenario and the future outlook of this therapy. As with DCTs, this chapter provides a holistic view on the various cell therapy products belonging to CAR-Ts and their future sales potential.
Chapter 7 provides the detailed company profiles of the leading players in the market. Each company profile includes information on financial performance, geographical presence, marketed / pipeline drugs, recent collaborations and developments.
Chapter 8 is a collection of interview transcript(s)of the discussions which were held during the course of this study.
Chapter 9 summarizes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.
Chapters 10 and 11 are appendices, which provide the list of companies and tabulated data for all the figures presented in the report.
1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. Executive Summary
3. Cancer Therapeutics and Immuno-Oncology
3.1. Chapter Overview
3.2. The Four Pillars of Cancer Therapy
3.3. Immunotherapy: Gaining A Strong Foothold
3.3.1. Activation and Suppression Immunotherapies
3.4. Immuno-Oncology (Cancer Immunotherapy)
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.2. By Product Class
3.5.2.1. Monoclonal Antibodies (mAbs)
3.5.2.2. Cytokines
3.5.2.3. Immune Checkpoint Inhibitors
3.5.2.4. Cell Based Therapies
4. Current Market Landscape
4.1. Scope and Observations
4.2. First DCT Reached the Market in 2007
4.3. Whole Cell Based Immunotherapies: Clinical and Preclinical Pipeline
4.3.1. DCTs are More Popular; CAR-Ts are Emerging
4.3.2. Four Products in Late Stage Clinical Development
4.4. DCT and CAR-Ts: A Comparison
4.5. DCT and CAR-Ts: Funding being Led by Venture Capital Firms
4.6. Overall Future Outlook
4.6.1. Scope and Forecast Methodology
4.6.2. Overall Market Size and Forecast, 2014 - 2024
5. Dendritic Cell Therapy: Key Molecules and Future Outlook
5.1. Introduction
5.2. Two Approved Products in the Market
5.3. Several Novel Molecules in the Pipeline
5.3.1. Focus on Solid Tumors
5.3.2. 50% of Molecules are in Phase II Clinical Trials and Above
5.3.3. Development Being Led by Small Biotech Firms
5.3.4. Gradual Evolution Towards Allogenic Dendritic Cells
5.4. PROVENGE (Dendreon Corporation)
5.4.1. Introduction
5.4.2. Mechanism of Action
5.4.3. Development Status
5.4.4. Key Clinical Trial Results
5.4.5. Manufacturing
5.4.6. Treatment Cost and Reimbursement
5.4.7. Historical Sales, 2010 – H1 2014
5.4.8. Competition for PROVENGE
5.4.9. PROVENGE Sales Forecast, 2014 - 2024
5.5. CreaVax-RCC (JW CreaGene)
5.5.1. Introduction
5.5.2. Development Status
5.5.3. Dosage, Treatment Cost and Manufacturing
5.6. AGS-003 (Argos Therapeutics)
5.6.1. Introduction
5.6.2. Arcelis: The Underlying Technology
5.6.3. Development Status
5.6.4. Key Clinical Trial Results
5.6.5. Dosage, Treatment Cost and Manufacturing
5.6.6. Target Population
5.6.7. Competition for AGS-003
5.6.8. Collaborations
5.6.9. AGS-003 Sales Forecast, 2014 - 2024
5.7. DCVax-L (Northwest Biotherapeutics)
5.7.1. Introduction
5.7.2. Prevalence of Disease
5.7.3. Mechanism of Action
5.7.4. Development Status
5.7.5. Dosage, Treatment Cost and Manufacturing
5.7.6. DCVax-L Sales Forecast, 2014 – 2024
5.8. DCVAC/PCa (SOTIO)
5.8.1. Introduction
5.8.2. Active Cellular Immunotherapy: The Underlying Technology
5.8.3. Mechanism of Action
5.8.4. Prevalence of Disease
5.8.5. Development Status
5.8.6. Dosage, Treatment Cost and Manufacturing
5.8.7. DCVAC/PCa Sales Forecast, 2014 - 2024
5.9. Eltrapuldencel-T (NeoStem)
5.9.1. Introduction
5.9.2. Prevalence of Disease
5.9.3. Mechanism of Action
5.9.4. Development Status
5.9.5. Key Clinical Trial Results
5.9.6. Dosage, Treatment Cost and Manufacturing
5.9.7. Collaborations
5.9.8. Competitive Analysis
5.9.9. Eltrapuldencel-T Sales Forecast, 2014 - 2024
5.10. Overall Dendritic Cell Therapy Market, 2014 – 2024
5.11. Technological Developments
5.11.1. Allogenic Dendritic Cell Derived Therapies
5.11.2. Tolerogenic Dendritic Cells
5.12. Dendritic Cell Therapy: Roots Analysis’ Perspective
6. Chimeric Antigen Receptor-T Cell Therapy
6.1. Introduction
6.2. Structure of Chimeric Antigen Receptor
6.2.1. History of Development
6.2.2. No Marketed Product Yet; Novel Products in Pipeline
6.2.3. Development Being Led by Small Biotech Firms
6.2.4. CD19: The Most Sought After Target
6.2.5. Companies Moving Beyond Haematological Malignancies
6.3. CTL019 (Novartis)
6.3.1. Introduction
6.3.2. History of Development
6.3.3. Prevalence of Disease
6.3.4. Mechanism of Action
6.3.5. Development Status
6.3.6. Key Clinical Trial Results
6.3.7. Dosage, Treatment Cost And Manufacturing
6.3.8. Collaborations
6.3.9. CTL019 Sales Forecast, 2014 - 2024
6.4. JCAR (Juno Therapeutics)
6.4.1. Introduction
6.4.2. Mechanism of Action
6.4.3. Development Status
6.4.4. Key Clinical Trial Results
6.4.5. Dosage, Treatment Cost and Manufacturing
6.4.6. Collaborations
6.5. KTE-C19 (Kite Pharma)
6.5.1. Introduction
6.5.2. Mechanism of Action
6.5.3. Development Status
6.5.4. Key Clinical Trial Results
6.5.5. Dosage, Treatment Cost and Manufacturing
6.5.6. Collaborations
6.5.7. KTE-C19 Sales Forecast, 2014 - 2024
6.6. CD19 CAR (Takara Bio)
6.6.1. Introduction
6.6.2. Mechanism of Action
6.6.3. Development Status
6.6.4. Dosage, Treatment Cost and Manufacturing
6.6.5. Collaborations
6.6.6. CD19 CAR Sales Forecast, 2014 - 2024
6.7. EFGRvIII CAR (Kite Pharma)
6.7.1. Introduction
6.7.2. Mechanism of Action
6.7.3. Development Status
6.7.4. Dosage, Treatment Cost and Manufacturing Details
6.7.5. Collaborations
6.7.6. EGFRVIII CAR Sales Forecast, 2014 - 2024
6.8. ANTI-GD2 CAR (Bellicum Pharmaceuticals)
6.8.1. Introduction
6.8.2. Mechanism of Action
6.8.3. Development Status
6.8.4. Dosage
6.8.5. Collaborations
6.9. Overall CAR-T Therapy Market, 2014 – 2024
6.10. Technological Developments
6.10.1. Use of Safety Switch to Increase Safety
6.10.2. Use of Allogenic Sources
6.11. CAR-T Therapy: Roots Analysis’ Perspective
7. Company Profiles
7.1. Overview
7.2. Dendreon Corporation
7.2.1. Company Overview
7.2.2. Financial Information
7.2.3. Product Portfolio
7.2.4. Patent Portfolio
7.2.5. Partnerships
7.2.6. Future Outlook
7.3. JW CreaGene
7.3.1. Company Overview
7.3.2. Product Portfolio
7.3.3. Patent Portfolio
7.3.4. Partnerships
7.3.5. Future Outlook
7.4. Northwest Biotherapeutics
7.4.1. Company Overview
7.4.2. Financial Information
7.4.3. Product Portfolio
7.4.4. Patent Portfolio
7.4.5. Partnerships
7.4.6. Funding
7.4.7. Future Outlook
7.5. Argos Therapeutics
7.5.1. Company Overview
7.5.2. Financial Information
7.5.3. Product Portfolio
7.5.4. Patent Portfolio
7.5.5. Partnerships
7.5.6. Manufacturing
7.5.7. Funding
7.5.8. Future Outlook
7.6. NeoStem
7.6.1. Company Overview
7.6.2. Financial Information
7.6.3. Product Portfolio
7.6.4. Partnerships
7.6.5. Manufacturing
7.6.6. Future Outlook
7.7. SOTIO
7.7.1. Company Overview
7.7.2. Financial Information
7.7.3. Product Portfolio
7.7.4. Patent Portfolio
7.7.5. Partnerships
7.7.6. Manufacturing Facilities
7.8. Novartis
7.8.1. Company Overview
7.8.2. Financial Information
7.8.3. Product Portfolio
7.8.4. Partnerships
7.8.5. Manufacturing
7.8.6. Future Outlook
7.9. Juno Therapeutics
7.9.1. Company Overview
7.9.2. Financial Information
7.9.3. Product Portfolio
7.9.4. Patent Portfolio
7.9.5. Partnerships
7.9.6. Future Outlook
7.10. Kite Pharma
7.10.1. Company Overview
7.10.2. Financial Information
7.10.3. Product Portfolio
7.10.4. Partnerships
7.10.5. Future Outlook
7.11. Takara Bio
7.11.1. Company Overview
7.11.2. Financial Overview
7.11.3. Product Portfolio
7.11.4. Partnerships
7.11.5. Manufacturing
7.11.6. Future Outlook
7.12. Other Companies
7.12.1. Asterias Biotherapeutics
7.12.1.1. Stem cell and Regenerative Medicine Platform
7.12.1.2. DCT Pipeline
7.12.1.3. Partnerships
7.12.2. Bellicum Pharmaceuticals
7.12.2.1. CaspaCIDe Technology (Cell Elimination)
7.12.2.2. DeCIDe Technology (Cell Activation) / DCT Pipeline
7.12.3. Cellular Biomedicine Group
7.12.3.1. Regenerative Medicine and Cell Therapy
7.12.3.2. DCT Pipeline
7.12.3.3. Patent Portfolio
7.12.4. DCPrime BV
7.12.4.1. DCOne Platform
7.12.4.2. DCT Pipeline
7.12.4.3. Partnerships
7.12.5. Immunicum
7.12.5.1. COMBIG Platform /DCT Pipeline
7.12.5.2. CD70 Platform
7.12.5.3. Patent Portfolio
7.12.6. Kiromic
7.12.6.1. DCT Pipeline
7.12.6.2. Other Therapeutic and Diagnostic Technologies
7.12.7. MediGene
7.12.7.1. DCT Pipeline
7.12.7.2. T cell Immunotherapy Platform
7.12.7.3. Patent Portfolio
7.12.7.4. Partnerships
7.12.8. Prima BioMed
7.12.8.1. DCT Pipeline
7.12.8.2. Partnerships
7.12.9. bluebird bio
7.12.9.1. Gene Therapy Platform
7.12.9.2. CAR-T Pipeline
7.12.9.3. Partnerships
7.12.10. Cellectis
7.12.10.1. UCART Technology
7.12.10.2. CAR-T Pipeline
8. Interview Transcripts
9. Conclusion
9.1. Whole Cell Based Therapy: Expanding the Cancer Immunotherapeutics Market
9.2. The Emerging Market Reveals a Promising Future
9.3. Companies are Focussing on Development of In-house Technology/Platform
9.4. With A Healthy Growth Rate, We Expect It To Be A Multi Billion Market
9.5. Concluding Remarks
10. Appendix 1: Tabulated Data
11. Appendix 2: List of Companies and Organisations
Figure 2.1 DCT and CAR-T Clinical Trials: Market Map
Figure 3.1 Four Pillars of Cancer Therapy
Figure 3.2 Passive and Active Cancer Immunotherapies
Figure 4.1 Pipeline Analysis: Distribution by Type of Molecule
Figure 4.2 Pipeline Analysis: Distribution by Highest Phase of Development
Figure 4.3 Whole Cell based Therapy: Overall Sales Forecast, 2014 - 2024: Base Scenario (USD Million)
Figure 5.1 DCT Pipeline Analysis: Distribution of Molecules by Indication
Figure 5.2 DCT Pipeline Analysis: Distribution of Molecules by Highest Phase of Development
Figure 5.3 DCT Pipeline Analysis: Distribution of Molecules by Company
Figure 5.4 DCT Pipeline Analysis: Sources of Dendritic Cells
Figure 5.5 PROVENGE Sales, 2010 – H1 2014 (USD Million)
Figure 5.6 PROVENGE: Sales Forecast, 2014 - 2024, Base Scenario (USD Million)
Figure 5.7 AGS-003: Sales Forecast, 2014 – 2024, Base Scenario (USD Million)
Figure 5.8 DCVax-L: Sales Forecast, 2014 - 2024, Base Scenario (USD Million)
Figure 5.9 DCVAC/PCa: Sales Forecast, 2014 – 2024, Base Scenario (USD Million)
Figure 5.10 Geographical Distribution of Death Rate due to Skin Cancer (Cases per 100,000 Persons)
Figure 5.11 Eltrapuldencel-T: Sales Forecast, 2014 - 2024, Base Scenario (USD Million)
Figure 5.12 Overall DCT Forecast, 2014-2024 (USD Million)
Figure 5.13 Overall DCT Forecast (2014, 2019, 2024): Distribution by Vaccines
Figure 5.14 Drivers and Restraints of DCT
Figure 6.1 Development of CAR-T Cells
Figure 6.2 CAR-T Pipeline Analysis: Distribution of Molecules by Highest Phase of Development
Figure 6.3 CAR-T Pipeline Analysis: Distribution of Molecules by Company
Figure 6.4 CAR-T Pipeline Analysis: Distribution by Target
Figure 6.5 Incidence of Four Main Types of Leukaemia in the US, 2013 (%)
Figure 6.6 CTL019: Sales Forecast, 2014 - 2024, Base Scenario (USD Million)
Figure 6.7 KTE-C19: Sales Forecast, 2014 - 2024, Base Scenario (USD Million)
Figure 6.8 CD19 CAR: Sales Forecast, 2014 - 2024, Base Scenario (USD Million)
Figure 6.9 EGFRVIII CAR: Sales Forecast 2014 - 2024: Base Scenario (USD Million)
Figure 6.10 Overall CAR-T Forecast, 2014-2024 (USD Million)
Figure 6.11 Overall CAR-T Forecast (2017, 2021, 2024): Distribution by Therapy
Figure 6.12 Drivers and Restraints of CAR-T Therapy
Figure 7.1 Dendreon Corporation: Revenues (USD Million), 2010–H1 2014
Figure 7.2 Northwest Biotherapeutics: Revenues (USD), 2003-2013
Figure 7.3 Argos Therapeutics: Revenues, 2011-2013 (USD Million)
Figure 7.4 NeoStem: Revenues, 2012- 2013 (USD Million)
Figure 7.5 PPF Group: Revenues, 2010-2013 (EUR Million)
Figure 7.6 Novartis Healthcare: Revenue, 2013: Distribution by Operating Segments (USD Million)
Figure 7.7 Novartis Pharmaceuticals: Revenues, 2009-2013 (USD Million)
Figure 7.8 Takara Bio: Revenue, 2010-2014 (YEN Million)
Figure 7.9 Takara Bio: Revenue, 2014: Distribution by Operating Segments (YEN Million)
Figure 9.1 Whole Cell Therapy Market (USD Million), 2017, 2021 and 2024
Table 3.1 FDA Approved Antibody Based Therapeutics for Cancer
Table 4.1 DCT and CAR-Ts: Clinical and Preclinical Pipeline
Table 4.2 Comparison of DCT and CAR-Ts
Table 4.3 DCT and CAR-T Companies: Funding Rounds
Table 4.4 Whole Cell based Therapy: Current Development Phase and Expected Launch Years
Table 5.1 DCT: Clinical and Preclinical Pipeline
Table 5.2 PROVENGE: Current Status of Development
Table 5.3 Comparison of Recently Approved Drugs for mCRPC
Table 5.4 Advantages of PROVENGE Over Competitors
Table 5.5 CreaVax-RCC: Current Status of Development
Table 5.6 AGS-003: Current Status of Development
Table 5.7 Target Population for AGS-003 in the US, 2013
Table 5.8 Comparison of Drugs Approved for RCC
Table 5.9 AGS-003: Partnerships
Table 5.10 DCVax-L: Current Status of Development
Table 5.11 DCVAC/PCa: Current Status of Development
Table 5.12 Eltrapuldencel-T: Current Status of Development
Table 5.13 Comparison of Marketed Targeted Therapeutics for Melanoma
Table 5.14 Advantages of Eltrapuldencel-T
Table 5.15 DCT Forecast: Expected Launch Years
Table 6.1 CAR-T Therapy: Clinical and Preclinical Pipeline
Table 6.2 CTL019: Current Status of Development
Table 6.3 JCAR: Current Status of Development
Table 6.4 KTE-C19: Current Status of Development
Table 6.5 CD19 CAR: Current Status of Development
Table 6.6 EGFRvIII CAR-T: Current Status of Development
Table 6.7 Anti-GD 2-CAR: Current Status of Development
Table 6.8 CAR-T Forecast: Expected Launch Years
Table 7.1 Dendreon Corporation: Patent Portfolio
Table 7.2 JW CreaGene: Product Portfolio
Table 7.3 JW CreaGene: Patent Portfolio
Table 7.4 Northwest Biotherapeutics: Product Portfolio
Table 7.5 Northwest Biotherapeutics: Patent Portfolio
Table 7.6 AGS-003: Development Status
Table 7.7 Argos Therapeutics: Patent Portfolio
Table 7.8 Developmental status of DCVAC
Table 7.9 SOTIO: Patent Portfolio
Table 7.10 Asterias Biotherapeutics: DCT Pipeline, 2014
Table 7.11 Bellicum Pharmaceutical: DCT Pipeline, 2014
Table 7.12 CBMG: DCT Pipeline, 2014
Table 7.13 DCPrime: DCT Pipeline, 2014
Table 7.14 Immunicum: DCT Pipeline, 2014
Table 7.15 Kiromic: DCT Pipeline, 2014
Table 7.16 MediGene: DCT Pipeline, 2014
Table 7.17 PrimaBioMed: DCT Pipeline, 2014
Table 7.18 bluebird bio:CAR-T Pipeline, 2014
Table 7.19 Cellectis: CAR-T Pipeline, 2014
Table 10.1 Pipeline Analysis: Distribution by Type of Molecule
Table 10.2 Pipeline Analysis: Distribution by Highest Phase of Development
Table 10.3 Whole Cell based Therapy: Overall Sales Forecast, 2014 - 2024: Base Scenario (USD Million)
Table 10.4 Whole Cell based Therapy: Overall Sales Forecast, 2014 - 2024: Optimistic Scenario (USD Million)
Table 10.5 Whole Cell based Therapy: Overall Sales Forecast, 2014 - 2024: Conservative Scenario (USD Million)
Table 10.6 Pipeline Analysis: Distribution of Molecules by Indication
Table 10.7 Pipeline Analysis: Distribution of Molecules by Highest Phase of Development
Table 10.8 Pipeline Analysis: Distribution of Molecules by Company
Table 10.10 Pipeline Analysis: Sources of Dendritic Cells
Table 10.11 PROVENGE Sales, 2010 – H1 2014 (USD Million)
Table 10.12 PROVENGE: Sales Forecast, 2014 - 2024, Base Scenario (USD Million)
Table 10.13 PROVENGE: Sales Forecast, 2014 - 2024, Optimistic Scenario (USD Million)
Table 10.14 PROVENGE: Sales Forecast, 2014 - 2024, Conservative Scenario (USD Million)
Table 10.15 AGS-003: Sales Forecast, 2014 - 2024: Base Scenario (USD Million)
Table 10.16 AGS-003: Sales Forecast, 2014 - 2024: Optimistic Scenario (USD Million)
Table 10.17 AGS-003: Sales Forecast, 2014 - 2024: Conservative Scenario (USD Million)
Table 10.18 DCVax-L: Sales Forecast, 2014 - 2024, Base Scenario (USD Million)
Table 10.19 DCVax-L: Sales Forecast, 2014 - 2024, Optimistic Scenario (USD Million)
Table 10.20 DCVax-L: Sales Forecast, 2014 - 2024, Conservative Scenario (USD Million)
Table 10.21 DCVAC/PCa: Sales Forecast, 2014 – 2024, Base Scenario (USD Million)
Table 10.22 DCVAC/PCa: Sales Forecast, 2014 – 2024, Optimistic Scenario (USD Million)
Table 10.23 DCVAC/PCa: Sales Forecast, 2014 – 2024, Conservative Scenario (USD Million)
Table 10.24 Geographical Distribution of Death Rate due to Skin Cancer (Cases per 100,000 Persons)
Table 10.25 Eltrapuldencel-T: Sales Forecast, 2014 - 2024, Base Scenario (USD Million)
Table 10.26 Eltrapuldencel-T: Sales Forecast, 2014 - 2024, Optimistic Scenario (USD Million)
Table 10.27 Eltrapuldencel-T: Sales Forecast, 2014 - 2024, Conservative Scenario (USD Million)
Table 10.28 Overall DCT Forecast, 2014-2024 (USD Million)
Table 10.29 Overall DCT Forecast, 2014, 2019, 2024: Distribution by Vaccine
Table 10.30 CAR-T Pipeline Analysis: Distribution of Molecules by Highest Phase of Development
Table 10.31 CAR-T Pipeline Analysis: Distribution of Molecules by Company
Table 10.32 CAR-T Pipeline Analysis: Distribution by Target
Table 10.33 Incidence of Four Main Types of Leukaemia in the US, 2013 (%)
Table 10.34 CTL019: Sales Forecast, 2014 - 2024, Base Scenario (USD Million)
Table 10.35 CTL019: Sales Forecast, 2014 - 2024, Optimistic Scenario (USD Million)
Table 10.36 CTL019: Sales Forecast, 2014 - 2024, Conservative Scenario (USD Million)
Table 10.37 KTE-C19: Sales Forecast, 2014 - 2024, Base Scenario (USD Million)
Table 10.38 KTE-C19: Sales Forecast, 2014 - 2024, Optimistic Scenario (USD Million)
Table 10.39 KTE-C19: Sales Forecast, 2014 -2024, Conservative Scenario (USD Million)
Table 10.40 CD19 CAR: Sales Forecast, 2014 - 2024, Base Scenario (USD Million)
Table 10.41 CD19 CAR: Sales Forecast, 2014 - 2024, Optimistic Scenario (USD Million)
Table 10.42 CD19 CAR: Sales Forecast, 2014 - 2024, Conservative Scenario (USD Million)
Table 10.43 EGFRVIII CAR: Sales Forecast, 2014 - 2024: Base Scenario (USD Million)
Table 10.44 EGFRVIII CAR: Sales Forecast, 2014 – 2024, Optimistic Scenario (USD Million)
Table 10.45 EGFRVIII CAR: Sales Forecast, 2014 – 2024, Conservative Scenario (USD Million)
Table 10.46 Overall CAR-T Forecast, 2014-2024 (USD Million)
Table 10.47 Overall CAR-T Forecast, 2017, 2021, 2024: Distribution by Molecule
Table 10.48 Dendreon Corporation: Revenues (USD Million), 2010–H1 2014
Table 10.49 Northwest Biotherapeutics: Revenues (USD), 2003-2013
Table 10.50 Argos Therapeutics: Annual Revenues, 2011-2013 (USD Million)
Table 10.51 NeoStem: Annual Revenues 2012- 2013 (USD Million)
Table 10.52 PPF Group: Annual Revenues 2010-2013 (EUR Million)
Table 10.53 Novartis Healthcare: Distribution by Operating Segments, 2013 (USD Million)
Table 10.54 Novartis Pharmaceuticals: Annual Revenues, 2009-2013 (USD Million)
Table 10.55 Takara Bio: Annual Revenue, 2010-2014 (YEN Million)
Table 10.56 Takara Bio: Revenue Distribution by Operating Segment, 2014 (YEN Million)
Table 10.57 Whole Cell Therapy Market 2017, 2021 and 2024 (USD Billion)
The following companies and organisations have been mentioned in this report.